8-K: Kymera Therapeutics Announces Exceptional Phase 1 Results for Oral STAT6 Degrader KT-621, Exceeding Expectations and Rivaling Dupilumab

Kymera Therapeutics, Inc. reported highly positive first-in-human Phase 1 clinical trial results for KT-621, an investigational oral STAT6 degrader, demonstrating robust STAT6 degradation, favorable safety, and promising Th2 biomarker reductions comparable or superior to dupilumab.

Summary

• Kymera Therapeutics completed a double-blind, placebo-controlled Phase 1 healthy volunteer trial for KT-621, enrolling 118 subjects across single ascending dose (SAD) and multiple ascending dose (MAD) cohorts.
• KT-621 exhibited a favorable pharmacokinetic profile with rapid absorption (median tmax of 2-4 hours), a half-life of 9-36 hours, dose-proportional exposure, and steady-state achieved by Day 4.
• The drug demonstrated rapid, deep, and prolonged STAT6 degradation, achieving over 90% mean STAT6 degradation in blood across all SAD doses starting at 6.25 mg, and complete degradation (over 95% mean reduction or below LLOQ) in both blood and skin at MAD doses of 50 mg or greater.
• Impact on Th2 biomarkers was observed, with median TARC reduction up to 37% and median Eotaxin-3 reduction up to 63% at Day 14, which the company believes are comparable or superior to published dupilumab results.
• KT-621's safety profile was undifferentiated from placebo, with no serious adverse events (SAEs), no severe AEs, no treatment-related adverse events (TRAEs) in more than one subject, and no clinically relevant changes in vital signs, laboratory tests, or ECGs.
• The company's KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients is ongoing, with data expected in the fourth quarter of 2025.
• Two parallel Phase 2b trials in AD and asthma are planned to commence in the fourth quarter of 2025 and first quarter of 2026, respectively, aiming to accelerate development towards Phase 3 registration studies across multiple Th2 indications.

Sentiment

Score: 9

Explanation: The document conveys an overwhelmingly positive sentiment, highlighting exceptional Phase 1 clinical trial results for KT-621, which exceeded company expectations in terms of efficacy, safety, and biomarker impact. The direct comparison to dupilumab, suggesting comparable or superior performance in key areas, significantly de-risks the program and indicates strong potential for a first-in-class oral therapeutic.

Positives

• KT-621's Phase 1 healthy volunteer data surpassed Kymera's target product profile, significantly de-risking the program and validating its oral, biologics-like profile.
• Achieved >90% mean STAT6 degradation in blood at all doses above 1.5 mg, demonstrating excellent potency.
• Complete STAT6 degradation was achieved in both blood and skin at all MAD doses of 50 mg or greater.
• KT-621's impact on Th2 biomarkers (TARC reduction up to 37%, Eotaxin-3 reduction up to 63%) was reported as comparable or superior to published dupilumab results.
• The safety profile of KT-621 was undifferentiated from placebo, with no serious adverse events, no severe adverse events, and no treatment-related adverse events in more than one subject, even at doses 16-fold above the 90% degradation level.

Risks

• Cross-trial comparisons between KT-621 and dupilumab may not be reliable as no head-to-head trials have been conducted, and Phase 1 data may not be directly comparable due to differences in molecule composition, trial protocols, dosing regimens, and patient populations.
• The results or interim results of current preclinical studies and clinical trials may not be predictive of future results in connection with current or future preclinical and clinical trials.
• There are inherent uncertainties in the initiation, timing, and design of future clinical trials, as well as the availability and timing of data from ongoing and future trials.
• The company's ability to successfully demonstrate the safety and efficacy of its drug candidates is subject to risk.
• The timing and outcome of the company's planned interactions with regulatory authorities are uncertain.
• Risks associated with obtaining, maintaining, and protecting intellectual property.
• Risks related to the company's relationships with its existing and future collaboration partners.
• The availability of funding sufficient for operating expenses and capital expenditure requirements.

Future Outlook

Kymera Therapeutics plans to accelerate KT-621 development by initiating two parallel Phase 2b trials in atopic dermatitis and asthma in late 2025 and early 2026, respectively. These studies are intended to enable dose selection for subsequent parallel Phase 3 registration studies across multiple Th2 dermatology, gastroenterology, and respiratory indications, aiming to transform treatment paradigms for over 130 million patients globally.

Management Comments

• Nello Mainolfi, PhD, Founder, President and CEO, stated: "Our primary objective was to demonstrate that KT-621 could achieve robust STAT6 degradation in blood and skin that was well tolerated, and these results go well beyond our expectations."
• Dr. Mainolfi also commented: "Across every measure, the KT-621 Phase 1 results were exceptional. We exceeded our 90% STAT6 degradation target even at single doses as low as 6.25 mg, which supports KT-621s excellent potency profile."
• He further noted: "Complete degradation was achieved by KT-621 in both blood and skin in all MAD cohorts at or above 50 mg. Importantly, KT-621 was well tolerated with a safety profile undifferentiated from placebo..."
• Dr. Mainolfi highlighted: "The Th2 biomarker results were very encouraging as well... and were comparable or superior to published dupilumab results."

Industry Context

KT-621 is positioned as a potentially first-in-class oral STAT6 degrader, targeting the IL-4/IL-13 signaling pathway, which is a central driver of Th2 inflammation in various immunological diseases. This approach aims to offer the convenience of an oral medicine with the potential for biologics-like activity, potentially broadening patient access compared to existing injectable biologics like dupilumab, which also targets this pathway.

Comparison to Industry Standards

• The company believes KT-621's median TARC reduction of up to 37% at Day 14 is comparable or superior to what was observed in the dupilumab healthy volunteer study.
• KT-621's median Eotaxin-3 reduction of up to 63% at Day 14 is reported as superior to what has been reported with dupilumab in asthma or chronic rhinosinusitis with nasal polyps (CRSwNP) patients, even at 52 weeks.
• Minimal IgE reductions were observed with KT-621, which is in line with findings from the dupilumab study in healthy volunteers, given low baseline IgE levels and short treatment duration.
• KT-621 aims to provide 'biologics-like activity' through an oral small molecule, offering a potential advantage in convenience over injectable biologics like dupilumab.

Stakeholder Impact

• **Shareholders**: The positive clinical trial results are highly likely to increase investor confidence and potentially lead to a positive impact on the company's stock price, as the program is significantly de-risked.
• **Patients**: The development of KT-621 offers the potential for a new, convenient (oral) and highly effective treatment option for a broad range of Th2-driven immuno-inflammatory diseases, including atopic dermatitis and asthma, potentially improving quality of life.
• **Employees**: The strong clinical data and clear path forward for KT-621 provide positive momentum and validation for the company's research and development efforts, potentially boosting morale and attracting talent.

Next Steps

• Data from the KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients is expected to be reported in the fourth quarter of 2025.
• Two parallel Phase 2b trials in AD and asthma are planned to start in the fourth quarter of 2025 and first quarter of 2026, respectively.
• These studies are intended to accelerate KT-621 development and enable dose selection for subsequent parallel Phase 3 registration studies.
• Future Phase 3 studies are planned across multiple Th2 dermatology, gastroenterology, and respiratory indications.

Key Dates

Recommendation

Keywords

Kymera Therapeutics, KT-621, STAT6 degrader, Targeted Protein Degradation, Immuno-inflammatory diseases, Atopic dermatitis, Asthma, Clinical trial, Phase 1, Healthy volunteer study, Dupilumab, Th2 biomarkers, Pharmacokinetics, Pharmacodynamics, Oral medicine